Healthcare systems globally face systemic inequities that affect marginalized groups. Digital health technologies (DHTs) have potential in addressing these disparities. The linked study aims to identify frameworks promoting health equity and assess DHTs' roles in implementing these guidelines. Additionally, it includes study analyses from multiple databases to guide future DHT development, ensuring equitable access and enhancing health equity.
What causes obesity in children and adolescents? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37918812/
The causal factors described in the scientific literature that have been shown to be related to obesity in childhood and adolescence are presented.
This review highlights key biopsychosocial factors contributing to obesity in children and adolescents, analyzing risks across six developmental stages, and summarizing causal factors from pre-conception to adolescence.
The Role of Obesity in Type 2 Diabetes Mellitus-An Overview - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38339160/
Obesity or excessive weight gain is identified as the most important and significant risk factor in the development and progression of type 2 diabetes mellitus (DM) in all age groups....
Obesity is a key risk factor for type 2 diabetes, with weight loss improving blood glucose control. A combined approach of diet, exercise, and lifestyle modifications is crucial for prevention and management.
Obesity-Related Ciliopathies: Focus on Advances of Biomarkers - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39126056/
Obesity-related ciliopathies, as a group of ciliopathies including Alström Syndrome and Bardet-Biedl Syndrome, exhibit distinct genetic and phenotypic variability. The understanding of these diseases is highly significant for understanding the...
This paper reviews obesity-related ciliopathies, like Alström and Bardet-Biedl syndromes, emphasizing primary cilia’s role, clinical variability, and the need for biomarker research to improve diagnosis, prognosis, and treatment insights.
Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38008609/
The novel term Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is proposed to replace non-alcoholic fatty liver disease (NAFLD) to highlight the close association with the metabolic syndrome. MASLD encompasses patients...
MASLD, replacing NAFLD, links liver steatosis to cardiometabolic risks, with CVD as a leading cause of death. Screening via SCORE2, lifestyle changes, statins, and anti-hypertensives are recommended treatments.

